38 results
8-K
EX-99.1
FHTX
Foghorn Therapeutics Inc
16 Apr 24
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
7:01am
Exhibit 99.1
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
CAMBRIDGE, Mass
8-K
EX-99.1
FHTX
Foghorn Therapeutics Inc
3 Jan 24
Foghorn Therapeutics Announces CFO Departure
4:18pm
for his leadership and commitment during his time at Foghorn”, said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “He has been … a valued member of our leadership team, and we wish him well in the future.”
The Company has commenced a formal search for a successor. Dr. Reine’s
8-K
EX-99.1
FHTX
Foghorn Therapeutics Inc
8 Sep 23
Regulation FD Disclosure
7:04am
cell types Molecular Glue PROTAC 61
Leadership Team, Board & Advisors FHD-286 is a Potent, Selective, Allosteric, Small Molecule Inhibitor … of the BRG1 and BRM subunits of the BAF complex EXPERTISE ACROSS DRUG DISCOVERY, CLINICAL DEVELOPMENT AND COMMERCIALIZATION
| PROVEN LEADERSHIP TEAM 63 ADRIAN
8-K
EX-99.1
FHTX
Foghorn Therapeutics Inc
8 Aug 23
Foghorn Therapeutics Announces Chief Medical Officer Succession
7:05am
services through early January 2024.
“I want to thank Sam for his leadership and many contributions to Foghorn over the past four years. He joined
8-K
EX-99.2
fpko67qeuejcv64h
4 Aug 23
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
7:05am
8-K
EX-99.1
6bte3 x8ul3st9ho
28 Jun 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
qfvkp5q
5 Jun 23
Regulation FD Disclosure
7:02am
8-K
EX-99.2
tqgoqo ds
8 May 23
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
7:03am
8-K
EX-99.2
o42bu7o6
8 Nov 22
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
7:08am
8-K
EX-99.2
b9fc6vza ta1s5
26 Oct 22
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
7:08am
8-K
EX-99.1
pq7dcaed
31 Aug 22
Foghorn Therapeutics Announces Change to Board of Directors
4:12pm
8-K
EX-99.2
lnr4fxbf1
23 Aug 22
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
7:04am
8-K
EX-99.2
yzvpzw5mbbhb2cbc8ur
9 Aug 22
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
7:06am
8-K
EX-99.1
0y7un65fx69
8 Jun 22
Regulation FD Disclosure
7:05am
8-K
EX-99.1
yc0scpjkceq0r65
19 May 22
Regulation FD Disclosure
4:11pm
8-K
EX-99.2
hvdofm500c
9 May 22
Foghorn Therapeutics Provides First Quarter 2022 Corporate Update
7:06am